# A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA

> **NCT05778877** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Selecta Biosciences, Inc.**

## Conditions studied

- Methylmalonic Acidemia (MMA)

## Interventions

- **DRUG:** SEL-302

## Key facts

- **NCT ID:** NCT05778877
- **Lead sponsor:** Selecta Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12-19
- **Primary completion:** 2025-08
- **Final completion:** 2029-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decided by sponsor
- **Last updated:** 2024-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05778877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05778877, "A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05778877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*